NTC-801 is under clinical development by Nissan Chemical and currently in Phase II for Arrhythmias. According to GlobalData, Phase II drugs for Arrhythmias have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NTC-801’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NTC-801 overview

NTC-801 (BMS-914392) is under development for the treatment of atrial fibrillation and arrhythmias. It is an antiarrhythmic agent administered orally. NTC-801 acts by targeting acetylcholine-activated potassium channel (IKACh).

Nissan Chemical overview

Nissan Chemical is a chemical company that develops, manufactures and sells display, semiconductor and inorganic materials; herbicides, insecticides and fungicides; and basic and high-purity chemicals. The company conducts custom manufacturing, and provides process research services for pharmaceutical ingredients and intermediates from pre-clinical to commercial production stages. Nissan Chemical’s R&D offerings include analytical method development, stability testing, impurity identification, metabolite synthesis and filing of drug master files. The company also provides transportation, landscaping, engineering and fertilizer solutions. It serves agriculture, electronics, information and electronics, pharmaceuticals, and other industries in Far East Asia, Europe, North America and China among others. Nissan Chemical is headquartered in Tokyo, Japan.

For a complete picture of NTC-801’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.